Allergan - one of the world's prominent pharmaceutical companies - has announced bumper sales for the first quarter of 2012.
The organisation is renowned for conducting clinical research and producing innovative products in the eye care, neuromodulator, skin care and other specialty markets.
It has revealed that $1.36 billion (£840 million) worth of total sales were made in the first three months of the year.
This represented a nine per cent improvement on the corresponding period in 2011.
In terms of its pharmaceutical products, the firm saw the number of transactions increase by 10.8 per cent between January and March 2012.
The corporation provides products to more than 100 countries across the globe and although it is predominantly based in the US, it has a strong presence in the UK, with a base in Buckinghamshire.
"In the first quarter Allergan delivered strong operating results as we continued to benefit from product approvals and operating in many growing markets," commented Allergan president and chief executive officer David Pyott.